0001123292-25-000633.txt : 20251112 0001123292-25-000633.hdr.sgml : 20251112 20251112163531 ACCESSION NUMBER: 0001123292-25-000633 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20251112 DATE AS OF CHANGE: 20251112 EFFECTIVENESS DATE: 20251112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phio Pharmaceuticals Corp. CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 453215903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-563765 FILM NUMBER: 251473556 BUSINESS ADDRESS: STREET 1: 411 SWEDELAND ROAD STREET 2: SUITE 23-1080 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 411 SWEDELAND ROAD STREET 2: SUITE 23-1080 CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20111019 D 1 primary_doc.xml X0708 D LIVE 0001533040 Phio Pharmaceuticals Corp. 411 SWEDELAND ROAD SUITE 23-1080 KING OF PRUSSIA PA PENNSYLVANIA 19406 760-943-1088 DELAWARE Rxi Pharmaceuticals Corporation RXi Pharmaceuticals Corp Corporation true Robert J. Bitterman 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Director Executive Officer Patricia A. Bradford 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Director Jonathan Freeman 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Director Curtis Lockshin, Ph.D. 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Director David H. Deming 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Director Lisa Carson 411 Swedeland Road Suite 23-1080 King of Prussia PA PENNSYLVANIA 19406 Executive Officer Biotechnology Decline to Disclose 06b false 2025-11-04 false true true false 0 H.C. Wainwright & Co, LLC 375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 IL ILLINOIS NY NEW YORK TX TEXAS 25931342 1415796 24515546 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 5 1116498 0 $1,116,497.82 in cash and warrants to purchase up to 424,739 shares of common stock (4,500 with an exercise price of $2.8125, 71,145 with an exercise price of $3.1488, 349,094 with an exercise price of $2.875). 0 false Phio Pharmaceuticals Corp. /s/ Robert J. Bitterman Robert J. Bitterman President and Chief Executive Officer 2025-11-12